Cannapharmarx Inc.
0.0050+0.00 (+0%)
Oct 28, 4:00:00 PM EDT · OTC Markets OTCPK · CPMD · USD
Key Stats
Market Cap
3.31MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
8-K
Debt settlement agreements filed
CannaPharmaRX entered letter agreements with payment schedules on August 7, 2025, to settle debts owed to two key debtholders, A. Tal and Koze Investments. This move sidesteps further defaults while preserving cash for operational growth and product delivery. Details were previously noted in the June 30, 2025, 10-Q but omitted from exhibits until now. Agreements secure stability amid funding pressures.
10-Q
Q2 FY2025 results
CannaPharmaRx posted Q2 revenue of $231,608, up from zero a year ago yet still dwarfed by $852,818 in costs, yielding a $621,210 gross loss—worse than 2024's $171,364 hit from impairments alone. Operating loss widened to $840,980 from $517,824, driven by new royalty fees to related party Koze on 192,384 grams sold, while professional fees dropped as operations stabilized. Net loss hit $1,413,458, or $0.00 per share on 662.5 million diluted shares, versus last year's $5.4 million gain from derivative swings; the gap stems mainly from fair-value changes in conversion features and obligations. Cash ticked up to $16,975 on $1.1 million related-party loans, but free cash flow isn't disclosed in the 10-Q, and total debt exceeds $34 million amid defaults on leases and notes. Revenue first trickled in. A British Columbia Cease Trade Order lingers, blocking trades and conversions.
10-Q
Q1 FY2025 results
CannaPharmaRx posted Q1 revenue of $335K, up sharply from $26K a year ago, driven by $308K in cannabis sales to Germany's Adjupharm GmbH, yet gross loss widened to $503K from $437K as inventory impairments hit $480K from suboptimal THC levels. Operating loss narrowed to $668K from $790K, thanks to slashed general and administrative costs, while net loss of $691K—or $0.00 per share on 663M diluted shares—eased from $12M last year, the gap mainly from fair-value gains on derivatives and share obligations offsetting a $1.9M lease adjustment. Cash dipped to $1.2K amid $601K operating burn, propped by $600K in related-party loans, with total debt at $31.7M including a $5.8M lease liability and heavy related-party exposure. No free cash flow disclosed. Ongoing litigation with Ataraxia over a $15M contract claim lingers unresolved.
8-K
Expands to Germany with shipments
CannaPharmaRX announced on May 6, 2025, the completion of four shipments to Israel totaling over 664 kg at rising average prices from 1.20 to 1.90 CAD/gram, plus a first 227.5 kg shipment to Germany at 1.94 CAD/gram, marking entry into a new European market. Acting as an intermediary for other growers added revenue streams. Shipments expand international reach while cultivation upgrades target 150 kg monthly output exceeding CAD$300,000 in sales. Demand surges, yet capital needs loom for full facility activation.
10-K
FY2024 results
CannaPharmaRx posted $820,137 in revenue for FY2024 ended December 31, 2024, its first full year of sales after securing Health Canada licenses, but absorbed a $9.9 million net loss amid startup hurdles. Q4 saw initial momentum with product sales kicking off, though gross margins suffered from $1.9 million inventory impairment tied to suboptimal THC levels in early batches, driving a $2.9 million gross loss overall. Operating expenses dropped 57% y/y to $671,330, thanks to slashed admin and payroll costs, yet other expenses ballooned on debt interest and a $3.4 million hit from the LTB deal's share obligation. Cash dwindled to $2,156 with negative operating flow of $1.7 million, propped by $1.7 million in financing; no dividends or buybacks, capex nil. Sales are nascent. Regulatory shifts in cannabis could stall export plans to Europe and Israel.
IPO
Employees
Sector
Industry
ACB
Aurora Cannabis Inc.
5.01-0.08
AKAN
Akanda Corp.
1.94-0.16
CBSTF
THE CANNABIST COMPANY HOLDINGS
0.09+0.00
CRLBF
Cresco Labs Inc.
1.20-0.04
CRON
Cronos Group Inc. Common Share
2.49+0.02
CURLF
Curaleaf Hldgs Inc.
2.82-0.05
MRMD
MariMed Inc.
0.13-0.01
NXEN
Nexien BioPharma, Inc.
0.01+0.00
PNXP
Pineapple Express Cannabis Comp
0.00+0.00
YCBD
cbdMD, Inc.
1.03+0.01